Compare PUBM & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | TOI |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Nursing Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 444.1M |
| IPO Year | 2020 | N/A |
| Metric | PUBM | TOI |
|---|---|---|
| Price | $9.18 | $3.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $18.45 | $6.00 |
| AVG Volume (30 Days) | 659.3K | ★ 2.9M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $288,382,000.00 | ★ $461,039,000.00 |
| Revenue This Year | N/A | $28.51 |
| Revenue Next Year | $0.49 | $23.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.67 |
| 52 Week Low | $7.01 | $0.17 |
| 52 Week High | $17.32 | $4.88 |
| Indicator | PUBM | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 59.39 |
| Support Level | $8.91 | $2.99 |
| Resistance Level | $9.24 | $3.32 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 65.48 | 86.61 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.